Advancing pediatric psychiatry: The convergence of precision therapy, neurofeedback, neurostimulation, and immersive technologies

Introduction Pediatric mental health disorders–ranging from anxiety and depression to autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD)–affect nearly 15%–20% of children globally, yet treatment outcomes remain suboptimal due to the one-size-fits-all paradigm of traditional psychiatry.[1] In India, the burden is particularly acute, with 50 million children estimated to have mental health conditions even prepandemic, 80%–90% of whom lacked access to care.[2] The COVID-19 crisis exacerbated these challenges, as lockdowns disrupted routines, increased screen time, and intensified familial stressors. Studies from India reveal that 23% of children developed behavioral or emotional problems during lockdowns, with peer issues (43%) and conduct disorders (26%) being most prevalent.[3] Excessive screen time–linked to ASD, depression (10%–25%), and anxiety–emerged as a key risk factor, compounded by metabolic disruptions like sleep disturbances and sedentary lifestyles.[4,5] Meanwhile, socioeconomic disparities amplified vulnerabilities, with children in poverty or overcrowded homes facing 2–3 times higher rates of emotional problems.[6] Today, a transformative shift is underway, driven by the convergence of precision medicine, neurotechnology, and immersive digital tools. This editorial explores how integrating these innovations can redefine care for young patients while addressing ethical and practical challenges in a postpandemic landscape. Biomarkers to Tailored Therapies The era of “trial-and-error” prescribing is giving way to biomarker-driven approaches. Genetic testing, neuroimaging, and artificial intelligence (AI)-powered algorithms now enable clinicians to predict individual responses to medications or behavioral therapies. For example, pharmacogenomic testing can identify children with CYP450 enzyme polymorphisms, reducing adverse drug reactions in antidepressants by up to 30%.[7] Similarly, machine learning models analyzing functional magnetic resonance imaging (MRI) data have shown promise in predicting treatment outcomes for adolescents with depression, allowing clinicians to prioritize therapies with the highest likelihood of success.[8] Such precision avoids wasted time and mitigates the stigma of failed interventions–a critical consideration in developmental years. Rewiring Young Brains Neurofeedback, which trains patients to self-regulate brain activity via real-time electroencephalogram monitoring, has emerged as a noninvasive alternative for ADHD and anxiety. A 2023 meta-analysis found that neurofeedback improved attention scores in 65% of children with ADHD, rivaling pharmacological efficacy without side effects.[9] For refractory cases, neurostimulation techniques like transcranial magnetic stimulation (TMS) offer hope: A multicenter trial reported a 50% remission rate in adolescents with treatment-resistant depression after 6 weeks of TMS.[10] Even invasive approaches, such as responsive neurostimulation for pediatric epilepsy, are being repurposed to modulate mood circuits, underscoring the potential of “closed-loop” systems that adapt to neural activity in real time.[11] Healing through Virtual Worlds Virtual reality (VR) and augmented reality (AR) are bridging the gap between clinical settings and real-world challenges. VR exposure therapy, for instance, has reduced phobia-related anxiety in 80% of children by simulating controlled environments (e.g., crowded classrooms) while monitoring physiological responses.[12] For ASD, AR apps like Superpower Glass teach social cues by overlaying emotional labels onto real-world interactions, improving empathy scores by 45% in a meta-analysis.[13] These tools not only enhance engagement but also democratize access to high-quality interventions–a child in a rural clinic can now access the same immersive protocols as one in an urban academic center. Magnetic Resonance Imaging-navigated Transcranial Magnetic Stimulation in India In resource-limited settings like India, integrating MRI-navigated TMS into pediatric psychiatry offers transformative potential. TMS, combined with neurofeedback and immersive therapies, provides noninvasive, precision-based treatment for ASD, depression, and other disorders–bypassing medication barriers.[14] Telemedicine and AI-assisted protocols may further enhance feasibility. Studies confirm its ability to induce structural changes (e.g., increased cerebellar gray matter) and functional connectivity improvements in children with ASD.[15] MRI-navigated TMS faces challenges in developing countries like India, including high costs (e.g. BrainsWay systems) and limited rural MRI access, a shortage of trained specialists for motor threshold mapping, and regulatory gaps in pediatric guidelines beyond depression. However, India’s growing neuroinnovation landscape–exemplified by institutions like AIIMS advancing neurotechnology training–supports scalable adoption. Hub-and-spoke models linking metropolitan centers (e.g. Delhi, Mumbai) with tele-rehabilitation could democratize access. With strategic investments in cost-reduced devices and specialist training, MRI-navigated TMS could transform precision psychiatry for India’s 5 million + ASD children.[16] Ethical and Practical Issues Despite their promise, these technologies raise pressing questions. Neurostimulation in developing brains demands rigorous longitudinal safety data, as early interventions could inadvertently alter neural plasticity.[17] Similarly, VR/AR tools risk exacerbating inequities if cost or digital literacy barriers exclude underserved populations. Privacy is another concern: Wearable neurodevices collect sensitive neural data, necessitating robust safeguards against misuse.[18] Clinicians must also navigate informed consent complexities–how does a 10-year-old assent to a brain implant? While precision therapies and neurotechnologies show promise, safety limitations–particularly in pediatric populations–require further study, including long-term adverse effects and developmental impacts.[19] To realize this vision, pediatricians, psychiatrists, and basic scientists must take interdisciplinary action. Prioritizing pediatric-specific research is crucial, as most neurotechnologies are developed for adults. Clinicians also need training to effectively interpret biomarker data and integrate digital tools into practice. Ultimately, success requires active collaboration across sectors–including tech developers, neuroscientists, and policymakers–to responsibly balance innovation with ethical and practical considerations. Conclusion The fusion of precision psychiatry, neurotechnology, and immersive tools signals a new beginning for pediatric mental health. By replacing guesswork with personalized, data-driven care, we can do better to lives while upholding the ethical imperatives of “first, do no harm.” The challenge lies not in the science but in our willingness to collaborate, regulate, and innovate with compassion. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.